# Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea

> **NCT06533865** · PHASE3 · RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 114 (estimated)

## Conditions studied

- FHA (Functional Hypothalamic Amenorrhea)

## Interventions

- **DRUG:** Romosozumab
- **DRUG:** Placebo
- **DRUG:** Zoledronic acid

## Key facts

- **NCT ID:** NCT06533865
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-19
- **Primary completion:** 2028-10
- **Final completion:** 2029-04
- **Target enrollment:** 114 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06533865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06533865, "Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06533865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*